Cite
HARVARD Citation
Armstrong, A. et al. (n.d.). Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet oncology. 17 (3), pp. 378-388. [Online].